Vaccine that targets both spike and nucleocapsid proteins in SARS-CoV-2 virus found effective in test animals

A large team of researchers at the University of Texas Medical Branch, working with two colleagues from the University of Pennsylvania Perelman School of Medicine and two with the Mayo Clinic, has developed a vaccine for COVID-19 that targets both the spike and nucleocapsid proteins in the SARS-CoV-2 virus. In their paper published in the journal Science Translational Medicine, the group explains their approach to developing the new vaccine and describes how well it worked in test mice and hamsters.